Barclays’s Usana Health Sciences USNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$616K Sell
35,241
-14,030
-28% -$278K ﹤0.01% 3064
2025
Q4
$967K Buy
49,271
+18,068
+58% +$375K ﹤0.01% 3450
2025
Q3
$860K Sell
31,203
-7,410
-19% -$228K ﹤0.01% 3457
2025
Q2
$1.18M Buy
38,613
+9,402
+32% +$267K ﹤0.01% 3228
2025
Q1
$788K Sell
29,211
-1,856
-6% -$58.8K ﹤0.01% 3251
2024
Q4
$1.11M Buy
31,067
+3,330
+12% +$125K ﹤0.01% 3308
2024
Q3
$1.05M Buy
27,737
+14,647
+112% +$602K ﹤0.01% 3320
2024
Q2
$592K Sell
13,090
-5,950
-31% -$274K ﹤0.01% 2942
2024
Q1
$923K Sell
19,040
-7,662
-29% -$375K ﹤0.01% 3177
2023
Q4
$1.43M Buy
26,702
+12,143
+83% +$614K ﹤0.01% 3176
2023
Q3
$853K Buy
14,559
+216
+2% +$13.5K ﹤0.01% 2453
2023
Q2
$904K Sell
14,343
-299
-2% -$19K ﹤0.01% 2374
2023
Q1
$921K Sell
14,642
-3,612
-20% -$216K ﹤0.01% 2791
2022
Q4
$971K Buy
18,254
+15,060
+472% +$816K ﹤0.01% 2830
2022
Q3
$179K Sell
3,194
-2,030
-39% -$134K ﹤0.01% 3269
2022
Q2
$379K Sell
5,224
-4,320
-45% -$322K ﹤0.01% 3052
2022
Q1
$758K Sell
9,544
-8,071
-46% -$728K ﹤0.01% 2607
2021
Q4
$1.78M Sell
17,615
-2,922
-14% -$291K ﹤0.01% 2456
2021
Q3
$1.89M Buy
20,537
+4,705
+30% +$453K ﹤0.01% 2399
2021
Q2
$1.62M Sell
15,832
-7,291
-32% -$732K ﹤0.01% 2337
2021
Q1
$2.26M Buy
23,123
+2,635
+13% +$240K ﹤0.01% 2173
2020
Q4
$1.58M Sell
20,488
-472
-2% -$36.5K ﹤0.01% 2430
2020
Q3
$1.54M Buy
20,960
+4,962
+31% +$398K ﹤0.01% 2321
2020
Q2
$1.17M Buy
15,998
+1,751
+12% +$137K ﹤0.01% 2618
2020
Q1
$823K Sell
14,247
-6,962
-33% -$484K ﹤0.01% 3156
2019
Q4
$1.67M Sell
21,209
-3,451
-14% -$254K ﹤0.01% 3189
2019
Q3
$1.69M Buy
24,660
+398
+2% +$26.7K ﹤0.01% 3079
2019
Q2
$1.93M Sell
24,262
-2,325
-9% -$184K ﹤0.01% 2963
2019
Q1
$2.23M Buy
26,587
+14,002
+111% +$1.46M ﹤0.01% 2455
2018
Q4
$1.48M Sell
12,585
-1,858
-13% -$215K ﹤0.01% 2710
2018
Q3
$1.74M Buy
14,443
+6,427
+80% +$798K ﹤0.01% 3040
2018
Q2
$925K Sell
8,016
-2,427
-23% -$266K ﹤0.01% 3370
2018
Q1
$898K Buy
10,443
+3,105
+42% +$240K ﹤0.01% 3340
2017
Q4
$543K Buy
7,338
+717
+11% +$48K ﹤0.01% 3738
2017
Q3
$383K Sell
6,621
-23,195
-78% -$1.37M ﹤0.01% 3871
2017
Q2
$1.91M Buy
29,816
+18,615
+166% +$1.15M ﹤0.01% 2290
2017
Q1
$646K Sell
11,201
-20,632
-65% -$1.23M ﹤0.01% 3150
2016
Q4
$1.95M Buy
31,833
+13,285
+72% +$866K ﹤0.01% 2147
2016
Q3
$1.28M Sell
18,548
-3,282
-15% -$217K ﹤0.01% 2394
2016
Q2
$1.22M Sell
21,830
-13,034
-37% -$786K ﹤0.01% 2439
2016
Q1
$2.11M Buy
34,864
+32,144
+1,182% +$1.89M ﹤0.01% 1878
2015
Q4
$173K Sell
2,720
-2,816
-51% -$183K ﹤0.01% 4018
2015
Q3
$371K Buy
5,536
+5,026
+985% +$355K ﹤0.01% 3618
2015
Q2
$35K Buy
510
+164
+47% +$10.4K ﹤0.01% 5372
2015
Q1
$19K Sell
346
-304
-47% -$15.6K ﹤0.01% 5868
2014
Q4
$33K Sell
650
-990
-60% -$48.6K ﹤0.01% 6010
2014
Q3
$61K Sell
1,640
-97,082
-98% -$3.5M ﹤0.01% 5721
2014
Q2
$3.85M Buy
98,722
+87,218
+758% +$3.24M ﹤0.01% 1997
2014
Q1
$432K Buy
11,504
+10,672
+1,283% +$373K ﹤0.01% 4083
2013
Q4
$31K Buy
832
+224
+37% +$8.57K ﹤0.01% 6477
2013
Q3
$26K Sell
608
-176
-22% -$7.06K ﹤0.01% 6415
2013
Q2
$29K Buy
+784
New +$23.8K ﹤0.01% 6649

Other funds holding USNA

Barclays's USNA Position: Q1 2026 in Review

Barclays reduced its Usana Health Sciences (USNA) stake by 28% in Q1 2026, selling an estimated $278K and leaving 35,241 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #3064.

Barclays first reported a position in USNA in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.85M in Q2 2014. 139 funds tracked by Wall St. Rank hold USNA as of Q1 2026.

  • Barclays held 35,241 shares of Usana Health Sciences worth $616K as of Q1 2026.
  • Barclays sold 14,030 Usana Health Sciences shares in Q1 2026, an estimated $278K.
  • Usana Health Sciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3064 holding.
  • Barclays first reported a position in Usana Health Sciences in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Usana Health Sciences position peaked at $3.85M in Q2 2014.
  • 139 funds tracked by Wall St. Rank held Usana Health Sciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.